Skip to main content
Equibles
BTAI logo

BTAI · BioXcel Therapeutics, Inc.

Track BTAI — free

Use BTAI with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.07 -0.04 (-37.11%) At close · Sep 4
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$2.31M
Shares
31.31M

BTAI metrics

66 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.07
Market cap
$2.31M

Price action

19 metrics
Price change (1W)
-59.2%
Price change (30D)
-91.1%
Price change (3M)
-93.3%
Price change (6M)
-95.0%
Price change (YTD)
-95.4%
Price change (1Y)
-97.9%
Trailing year
Price change (5Y)
—
52-week high
$4.23
52-week low
$0.07
Change from 52-week high
-98.3%
Change from 52-week low
+0.0%
Annualized volatility
127.5%
Beta
2.4
RSI (14D)
20.2
Price vs SMA 50
-91.2%
Price vs SMA 200
-94.5%
Avg volume (3M)
6.11M
Relative volume
7.8
Average dollar volume
$1.56M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
31.31M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
128.0×
reciprocal yield 0.8%
EV / EBITDA
—
EV / EBIT
—
P / sales
4.5×
reciprocal yield 22.2%
P / book
—
FCF yield
-1,519.7%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-2,115.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
155.9×
reciprocal yield 0.6%
EV / revenue historical average (5Y)
155.9×
reciprocal yield 0.6%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-12-08

Profitability

9 metrics
Gross margin
53.1%
Operating margin
-6,054.7%
Trailing 12 months
Net margin
-9,549.9%
Gross profit (TTM)
—
Operating profit (TTM)
−$44.93M
Net income (TTM)
−$70.86M
Trailing 12 months
Diluted EPS (TTM)
$-2.81
FCF margin
-6,860.4%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-1.59

Growth

11 metrics
Revenue growth YoY
+51.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$742,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+286.3%
Year over year · more shares
Revenue CAGR (3Y)
+19.6%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-246.1%
Debt / equity
—
Current ratio
0.2
EBITDA (TTM)
−$111.73M
Free cash flow (TTM)
−$50.90M
Quick ratio
0.2
Interest coverage
-2.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$91.61M
Latest balance sheet
Cash & equivalents
$12.84M
Total assets
$28.80M
Total debt
$104.45M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$50.90M
Capital expenditures (TTM)
$0
R&D (TTM)
$21.56M
SG&A (TTM)
$23.57M
Stock compensation (TTM)
$1.82M
R&D / revenue
2,905.7%
Stock compensation / revenue
245.8%

Ownership (13F)

3 metrics
13F filers
47
13F filer change QoQ
+7
Institutional ownership
19.7%

Short interest

3 metrics
Short interest
10.6%
Latest settlement · 4.2 days to cover
Days to cover
4.2d
Short-squeeze score
54 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1720893 CUSIP 09075P204 13F (30d) 38 filings 38 filers Visit website Investor relations